Recent advancements and clinical translation of cinnamaldehyde derivatives in therapeutics

This review systematically evaluates why CA derivatives have failed to transition from bench to bedside despite superior preclinical performance.

Cinnamaldehyde (CA) clinical translation is stymied by a biopharmaceutical paradox: promising in vitro efficacy is negated by poor aqueous solubility (≈1 mg/mL), rapid first-pass metabolism, and a short plasma half-life (≈1.7 h). Also, the reactive α,β-unsaturated aldehyde moiety often triggers Pan-Assay Interference (PAINS) behavior.

We identify three primary chemical strategies that circumvent native CA's limitations: (1) Aldehyde masking (e.g. N-oxide conversion in PX5-9), which improves aqueous solubility by >2000-fold; (2) α-substitution (e.g. α-bromo-4-chloro CA), which modulates Michael acceptor reactivity to achieve an 87-fold higher selectivity index than the parent compound; and (3) Stimuli-responsive polymer conjugation (e.g. ROS-labile thioacetals), which enables tumor-microenvironment-triggered CA release and reduces cytotoxicity to IC₅₀ ≫ 1600 µM in normal cells. While these derivatives show compelling in vivo efficacy in oncological, antiviral, and anti-inflammatory models, progress is halted by a lack of human pharmacokinetic profiling and 'safety bridging' toxicology.

The science of CA derivatives is more mature and future development must shift from broad scaffold exploration to targeted translational consortia focused on four priority leads (Compound 5, HCAG, PX5-9, and Compound 6f). Addressing the 'in vitro-in vivo disconnection' through chemoproteomic target validation and IND-enabling PK studies is the essential next step for advancing this reactive scaffold into clinical trials.